Sustained clinical benefit of ramucirumab plus erlotinib in EGFR mutated NSCLC, irrespective of the mutation type Sustained clinical benefit of ramucirumab plus erlotinib in EGFR mutated NSCLC, irrespective of the mutation type September 2020 ESMO 2020 Read more
2023 January Cancer trials Adagrasib with or without cetuximab effective in patients with colorectal cancer with mutated ... Read more
(sponsored) 2022 December Pharma News ADDING ABEMACICLIB TO FIRST LINE ENDOCRINE THERAPY RESULTS IN A CLINICALLY RELEVANT SURVIVAL B... Read more
2022 November Cancer trials No benefit of adjuvant atezolizumab in the treatment of renal cell carcinoma Read more
2022 November Cancer trials Pembrolizumab as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma Read more
2022 October Editor's pick Relevant literature for your daily practice selected by: Dirk Schrijvers Read more
